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NCYM is a cis-antisense gene of MYCN and is ampliﬁed in human neuroblastomas. High NCYM expression
is associated with poor prognoses, and the NCYM protein stabilizes MYCN to promote proliferation of
neuroblastoma cells. However, the molecular mechanisms of NCYM in the regulation of cell survival have
remained poorly characterized. Here we show that NCYM promotes cleavage of MYCN to produce the
anti-apoptotic protein, Myc-nick, both in vitro and in vivo. NCYM and Myc-nick were induced at G2/M
phase, and NCYM knockdown induced apoptotic cell death accompanied by Myc-nick downregulation.
These results reveal a novel function of NCYM as a regulator of Myc-nick production in human
neuroblastomas.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neuroblastoma is one of common solid childhood tumors that
originate from sympatho-adrenal tissues [1]. MYCN oncogene is
frequently ampliﬁed in high-risk neuroblastomas [2,3], and the
MYCN oncoprotein regulates transcription of various target genes
to promote the tumorigenesis [4]. Overexpression of MYCN in the
sympathetic nervous system is sufﬁcient to develop neuroblastoma
in mice [5], and concomitant activation of cell survival signals or
inhibition of apoptosis further induces metastatic tumors [6e8].
NCYM is a cis-antisense transcript of MYCN oncogene [9e11],
which has been thought to be a long non-coding RNA [11]. Recentlyhiba Cancer Center Research
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Inc. This is an open access article uwe reported that NCYM is a newly evolved coding gene which is
conserved only in a taxonomically-restricted group including
humans and monkeys [8]. NCYM is co-ampliﬁed with MYCN in
human neuroblastomas [8,10], and high NCYM expression is asso-
ciated with poor prognoses of the tumors [8]. NCYM stabilizes
MYCN through inhibition of GSK3b, and MYCN stimulates NCYM
transcription [8]. MYCN ampliﬁcation in human neuroblastomas
induces both MYCN and NCYM, and the positive auto-regulatory
loop between MYCN and NCYM keeps their expression at high
levels [8,12]. Furthermore, overexpression of MYCN and NCYM in
the sympathetic nervous system of mice frequently develops
metastatic tumors, inhibiting apoptotic cell death within the tu-
mors [8]; however the molecular mechanisms by which NCYM
regulates cell survival have remained elusive.
MYC family oncogenes encode transcription factors which
regulate a wide variety of biological phenomena, including devel-
opment and tumorigenesis [13,14]. Myc-nick has been identiﬁed as
the cleaved product of MYC family members [15], MYC and MYCN,
and function as anti-apoptotic proteins in transcriptional
regulation-independent manners [16]. MYC and MYCN are cleaved
by the Ca2þ dependent protease calpain to produce Myc-nick, a
cytoplasmic 42 kDa protein lacking the DNA binding domains [15].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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autophagosomes which are implicated in autophagy, leading to
cancer cell survival [16]. Moreover, Myc-nick increases acetylation
of a-tubulin through the recruitment of GCN5, an acetyltransferase,
and promotes migration of cancer cells [16]. Because NCYM directly
binds to MYCN and augments aggressiveness of neuroblastomas by
inhibiting apoptosis [8], we hypothesized that NCYM may regulate
Myc-nick in human neuroblastoma cells. In this study, we found
that NCYM promotes calpain-mediated Myc-nick production and
reduces apoptotic cell death at G2/M phase in MYCN-ampliﬁed
neuroblastoma cells.
2. Materials and methods
2.1. In vitro cleavage of MYC or MYCN
Puriﬁed MYCN (50 ng, Abnova, Taipei, Taiwan) was incubated
with 25 mM MG132, 250 ng of calpain (Abcam, San Francisco, CA,
USA) and increasing amounts (0, 25, 50, 100 ng) of puriﬁed NCYM
protein in buffer G [15] (30 mM TriseHCl pH 7.6, 100 mM NaCl,
10 mM CaCl2, 10 mM MgCl2, 50 mM ATP, 5% glycerol) for 1 h on ice,
and the samples were analyzed by western blot. Puriﬁcation of
NCYM protein was done as previously described [8]. Cleavage of
MYC (50 ng, Abnova) and MYCL (50 ng, Abnova) was performed as
described abovewith 100 ng of puriﬁed NCYM protein. For the time
course assays, MYC (50 ng, Abnova) or MYCN (50 ng, Abnova) was
incubated with 25 mMMG132 and 250 ng of calpain (Abcam), with
or without 100 ng puriﬁed NCYM protein, in buffer G for indicated
times and samples were analyzed by western blot. For the inhibi-
tion experiments, 50 ng of puriﬁed MYC or MYCN (Abnova) was
incubated with 25 mM MG132, with or without 2000 ng of calpain
(Abcam), 100 ng of puriﬁed NCYM protein and 100 mM calpeptin
(Calbiochem, San Diego, CA, USA) in buffer G for 3 h on ice and the
samples were analyzed by western blot.
2.2. GST-pulldown assay
For GST-pulldown assay, 0.5 mg of calpain protein (Abcam) was
incubated with 0.5 mg of GST protein or MYCN (Abnova) with or
without 0.5 mg of puriﬁed NCYM protein for 2 h at 4 C. Bound
complexes were recovered on glutathione-sepharose beads coated
with 1 mg/ml BSA, washed with buffer G (30 mM TriseHCl pH 7.6,
100 mM NaCl, 10 mM CaCl2, 10 mM MgCl2, 50 mM ATP, 5% glycerol
and protease inhibitors), boiled in Laemmli sample buffer and
analyzed by immunoblotting. PIC (Roche, Mannheim, Germany)
was used for protease inhibition.
2.3. Cell culture, infection, transfection, and RNA interference
Human neuroblastoma cell line CHP134 was maintained in
RPMI-1640 medium supplemented with heat-inactivated 10% fetal
bovine serum (FBS) (Gibco, Carlsbad, CA, USA). HEK293T cells were
cultivated in Dulbecco's modiﬁed Eagle's medium (Wako, Osaka,
Japan) supplemented with 10% heat-inactivated FBS. CHP134 has
ampliﬁed MYCN. Lentivirus was produced by co-transfecting cDNA
or shRNA expression plasmids with pCMVR and pMDG plasmids
into HEK293T cells using FuGene HD transfection reagent (Roche).
The NCYM shRNA expression plasmids contained pLKO.1-puro as
the backbone (Sigma, St Louis, MO, USA). At 24 and 48 h after
transfection, the viral supernatants were collected and mixed with
CHP134 cells. Construction of the expression vector pcDNA3-FLAG-
NCYM was previously described [8]. CHP134 cells were transfected
with pcDNA3-FLAG-NCYM using Lipofectamine 2000 transfection
reagent (Invitrogen, Karlsruhe, Germany) according to the manu-
facturer's instructions. The target sequences of the shRNAs usedwere as follows: NCYM sh-1 (N-cym 1 custom shRNA, Sigma) 50-
tggcaattgcttgtcattaaa-30, NCYM sh-2 (N-cym 2 custom shRNA,
Sigma) 50-gaggttgctcctgtgtaatta-30. The control shRNA (SHC002)
was purchased from Sigma.
2.4. Immunoblotting
We resolved cell proteins by SDS-PAGE before electro-blotting
onto PVDF membranes. We incubated the membranes with the
following primary antibodies overnight at 4 C: anti-MYCN (1:1000
dilution; Calbiochem and Cell Signaling, Danvers, MA, USA), anti-
MYC (1:1000 dilution; Santa Cruz, CA, USA), anti-NCYM (1:1000
dilution [8]), anti-acetyl a-tubulin (1:1000 dilution; Abcam), anti-
a-tubulin (1:1000 dilution; Cell Signaling). The membranes were
then incubated with a horseradish peroxidase-conjugated sec-
ondary antibody (anti-rabbit IgG at 1:2000e1:4000 dilution or
anti-mouse IgG at 1:2000 dilution; both from Cell Signaling) and
the bound proteins were visualized using a chemiluminescence-
based detection kit (ECL and ECL pro kit, Amersham, Piscataway,
NJ, USA; ImmunoStar LD, Wako). For quantiﬁcation of immuno-
blotting analysis, we used Molecular Imager® VersaDoc™MP 5000
System (Bio-Rad laboratories Inc. CA, USA).
2.5. Double thymidine block and cell distribution
CHP134 cells were washed twice with 1  PBS and RPMI-1640
containing 2 mM thymidine was added for 18 h. The medium was
removed and cells were washed with 1  PBS and maintained in
RPMI-1640 for 9 h to release cells. The medium was replaced with
RPMI-1640 containing 2 mM thymidine for 17 h. After the second
block, thymidine was removed by washing with 1  PBS, and cells
were released by adding fresh medium. Cells were harvested at
indicated times and subjected to western blot and cell cycle dis-
tribution analyses. For cell cycle distribution analysis, cells were
collected at indicated times after the double thymidine block,
stained with propidium iodide (PI) and examined by ﬂow cytom-
etry (FACSCalibur, BD Biosciences, San Jose, CA, USA).
2.6. RNA isolation and quantitative real-time RT-PCR
Total RNA from CHP134 neuroblastoma cells was prepared using
an RNeasy Mini kit (Qiagen, Valencia, CA, USA) following the
manufacturer's instruction. cDNA was synthesized using Super-
Script II with random primers (Invitrogen). Quantitative real-time
RT-PCR (qRT-PCR) using an ABI PRISM 7500 System (Applied Bio-
systems, Foster City, CA, USA) was carried out using a SYBR green
PCR. The primer sets used were as follows: human NCYM, 50-
cgcccccttaggaacaagac-30 and 50-gcgcccctcttctttcaatt-30. The mRNA
levels of each of the genes were standardized by b-actin.
2.7. Terminal deoxynucleotidyl transferase UTP nick end labeling
(TUNEL) assays
CHP134 cells were transfected with the indicated shRNA with
50% lentiviral supernatant. Seventy-two hours after transfection, all
cells were collected by centrifugation at indicated times after
release of double thymidine block, attached onto the coverslips by
CYTOSPIN 4 (Thermo Fisher Scientiﬁc, Wilmington, DE, USA), and
ﬁxed in 4% paraformaldehyde for 1 h. Apoptotic cells were detected
by using an in situ cell death detection kit (Roche Applied Science
GmbH, Mannheim, Germany) according to the manufacturer's
protocol. The coverslips were mounted with DAPI-containing
mounting medium (Vector Laboratories, Burlingame, CA, USA)
and observed under a laser scanning confocal microscope (DMI
4000B; Leica, Wetzlar, Germany).
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All statementsarebasedonreplicatedexperiments (aminimumof
three times). All statistical signiﬁcancewas tested by Student's t-test.
3. Results
3.1. NCYM promotes the cleavage of MYC and MYCN in vitro
We investigated whether NCYM directly promotes the cleavage
of Myc family members in vitro. Calpain alone cleaved MYCN, and
Myc-nick levels increased with the addition of increasing amounts
of NCYM (Fig. 1A). Calpain at 250 ng/ml alone could not cleave MYC,
but the combination of NCYM and calpain resulted in Myc-nick
production (Fig. 1B, left panel). MYCL, which lacks the cleavage
site of calpain, didn't show band shifts by addition of calpain and
NCYM (Fig. 1B, right panel). Myc-nick production by calpain
occurred at earlier time points in the presence of NCYM (Fig. 1C, D)Fig. 1. NCYM promotes cleavages of MYC and MYCN to produce Myc-nick in vitro. (A) NCYM
representative of three independent experiments. (B) MYC, but not MYCL was cleaved in the
Cleavage of MYC or MYCN was increased in a time-dependent manner in the presence of NC
Calpeptin inhibits Myc-nick production induced by NCYM. Western blot. Results are represe
Calpain proteins were pulled down with GST-fused MYCN. Results are representative of thrand the NCYM-mediated Myc-nick production was partially
inhibited by the calpain inhibitor, calpeptin (Fig. 1E, F). Moreover,
GST-pulldown assays revealed that GST-fused MYCN interacted
with NCYM and calpain in the buffer of the in vitro cleavage assay
(Fig. 1G, right panel). Thus, NCYM promotes calpain-mediated Myc-
nick production in vitro, forming complex with MYCN.
3.2. NCYM positively regulates Myc-nick production
We next investigated Myc-nick production in CHP134 neuro-
blastoma cells using NCYM knockdown and overexpression. As
described previously [15,16], the cleaved form of MYCN, a cyto-
plasmic 42 kDa protein, was observed in the MYCN-ampliﬁed
neuroblastoma CHP134 cells. We also detected phosphorylated
Myc-nick [16], as indicated in Fig. 2A. In MYCN-ampliﬁed neuro-
blastoma cell line CHP134, knockdown of NCYM decreased Myc-
nick production (Fig. 2A, B), whereas overexpression of NCYM
increased production of Myc-nick (Fig. 2C, D).promoted Myc-nick production in a dose-dependent manner. Western blot. Results are
presence of NCYM. Results are representative for three independent experiments. (C, D)
YM. Western blot. Results are representative of three independent experiments. (E, F)
ntative of three independent experiments. (G) GST-pulldown assay. Puriﬁed NCYM and
ee independent experiments.
Fig. 2. NCYM increases Myc-nick production in human neuroblastoma cells. (A) Knockdown of NCYM decreased Myc-nick production. Western blot. The amounts of MYC or MYCN
were adjusted to normalize Myc-nick. Results are representative of six independent experiments. (B) Quantiﬁcation of western blotting analysis in NCYM knockdown cells. Myc-
nick levels were normalized to MYC or MYCN. Data represent the mean ± SEM from six independent experiments. (C) Overexpression of NCYM increased Myc-nick production. The
amounts of MYC or MYCN were adjusted to normalize Myc-nick. Results are representative of four independent experiments. (D) Quantiﬁcation of (C). Data represent the
mean ± SEM from four independent experiments.
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To investigate NCYM and Myc-nick protein levels throughout
the cell cycle, we synchronized CHP134 cells by double thymidine
block. Fluorescence activated cell sorting showed that CHP134 cells
were synchronized in G2/M phase at 7 h after double thymidine
block treatment (Fig. 3A, bottom panel). NCYM and Myc-nick pro-
tein levels rose at G2/M phase, accompanied by increased acety-
lated a-tubulin, whereas a-tubulin levels remained unchanged
throughout the cell cycle (Fig. 3A). No changes in NCYM mRNA
levels were detected in CHP134 cells (Fig. 3B).3.4. Knockdown of NCYM induces apoptosis at G2/M
We next examined whether NCYM inﬂuences the levels of Myc-
nick and acetylated a-tubulin by using shRNA-mediated NCYM
knockdown. At 72 h after transfection, cells were collected at 0, 4 or
7 h after the double thymidine block. Knockdown of NCYM
decreasedMyc-nick production, accompanied by decreased level of
acetyl a-tubulin at 7 h after the double thymidine block (Fig. 3C).
NCYM knockdown signiﬁcantly increased the number of apoptotic
cells relative to controls at G2/M phase (Fig. 3D, E). These dataindicate that NCYM downregulation is associated with decreased
levels of acetylated a-tubulin and Myc-nick at G2/M phase.4. Discussion
Myc-nick contributes to aggressiveness of cancer cells by
inhibiting apoptosis [16]; however, the upstream regulatory
mechanisms of Myc-nick production have been poorly character-
ized. In this study, we identiﬁed NCYM as a regulator of Myc-nick in
MYCN-ampliﬁed neuroblastoma cells. Puriﬁed NCYM and calpain
directly bound to MYCN, and NCYM augmented calpain-mediated
Myc-nick production. Since NCYM alone did not produce Myc-
nick, the interaction between MYCN, NCYM, and calpain may
facilitate efﬁcient Myc-nick production. NCYM-mediated Myc-nick
production was partially blocked by the treatment of a calpain in-
hibitor, calpeptin. Thus, calpain activity is one of the key de-
terminants for NCYM-dependent Myc-nick production.
High MYCN expression in mitotic phase maintains self-renewal
of MYCN-ampliﬁed neuroblastoma cells [17,18], and degradation of
MYCN induces asymmetric cell division [17,18], producing differ-
entiated neuroblastoma cells that will eventually die [18]. MYCN
degradation requires sequential phosphorylation by cyclin B/Cdk1
Fig. 3. NCYM knockdown decreases Myc-nick and induces apoptosis at G2/M phase. (A) The expressions of both Myc-nick and NCYM were increased and were accompanied by the
induction of acetyl a-tubulin. CHP134 human neuroblastoma cells were synchronized using double thymidine block, harvested at indicated times and subjected to western blot and
cell cycle distribution analyses. a-tubulin was used as a loading control. Results are representative of three independent experiments. (B) Quantitative real-time PCR (qRT-PCR) of
NCYMmRNA in CHP134 cells after double thymidine block. Relative mRNA expression was normalized to b-actin. Data show mean ± SEM of triplicated wells. Statistical signiﬁcance
was tested by Student's t-test. NS: not signiﬁcant. (C) Western blot analysis in shRNA-mediated NCYM knockdown cells at indicated times after double thymidine block. a-tubulin
was used as a loading control. Results are representative of three independent experiments. (D) Representative TUNEL assay images at G2/M phase. Results are representative of
three independent experiments. (E) Quantiﬁcation of apoptotic cells (D) presented as percentage of TUNEL-positive cells. Data represent the mean ± SEM from three independent
experiments. NS: not signiﬁcant. Scale bar, 50 mm.
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promotes accumulation of MYCN at spindle poles where MYCN is
destabilized by the ubiquitin-proteasome system [18]. Aurora ki-
nase A, which is an essential regulator of mitosis [20], interacts with
both MYCN and SCF ubiquitin ligase and stabilizes MYCN in mitotic
phase [21]. Aurora A inhibitors destabilize MYCN and suppress
progression ofMYCN-ampliﬁed neuroblastomas [22,23]. Therefore,
targeting mitotic MYCN is a promising strategy for treatment of
MYCN-ampliﬁed neuroblastomas. In this study, we found that
NCYM increases Myc-nick at G2/M phase. Since NCYM stabilizes
MYCN by inhibiting GSK3b [8], NCYM at G2/M may regulate the
amount of Myc-nick by two mechanisms: increasing the substrate
of calpain (full-length MYCN) and facilitating calpain-mediated
cleavage by the interaction with MYCN. Previous reports have
shown the signiﬁcance of Myc-nick-related genes in G2/M transi-
tion [24e28]. Inhibition of calpain induces aberrant mitosis and
prometaphase arrest due to activation of the spindle assembly
checkpoint [24]. GCN5 promotes the G2/M transition by inducing
a-tubulin acetylation [25] and the deletion of GCN5 augment cell
apoptosis and G2/M retardation [26]. Furthermore, acetylated a-
tubulin is involved in stabilization of a-tubulin, promoting anti-
mitotic drug resistance [27] and aggressiveness of cancers [28].Since Myc-nick promotes acetylation of a-tubulin via recruitment
of GCN5 [15], NCYM may inhibit apoptosis through Myc-nick-
mediated a-tubulin acetylation at G2/M phase. In accordance
with this idea, NCYM knockdown decreased acetylated a-tubulin at
G2/M phase and induced apoptotic cell death in CHP134 cells.
In conclusion, our ﬁndings suggest that NCYM promotes
calpain-mediated cleavage of MYCN and subsequent Myc-nick
production in neuroblastoma cells. This study provides a new
insight into the function of NCYM as a regulator of Myc-nick pro-
duction. Further studies are needed to examine whether NCYM-
mediated Myc-nick production could regulate polar ejection
forces through increased acetyl a-tubulin to override the mitotic
checkpoint.
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